Cigliano Antonio, Liao Weiting, Deiana Giovanni A, Rizzo Davide, Chen Xin, Calvisi Diego F
Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Biomedicines. 2024 Jul 22;12(7):1624. doi: 10.3390/biomedicines12071624.
Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years. In addition to the traditional chemically and dietary-induced HCC models, a broad spectrum of novel preclinical tools have been generated following the advent of transgenic, transposon, organoid, and in silico technologies to overcome this gloomy scenario. These models have become rapidly robust preclinical instruments to unravel the molecular pathogenesis of liver cancer and establish new therapeutic approaches against this deadly disease. The present review article aims to summarize and discuss the commonly used preclinical models for HCC, evaluating their strengths and weaknesses.
肝细胞癌(HCC)是主要的原发性肝癌,尽管近年来治疗取得了进展,但它仍然是全球最致命的癌症之一。除了传统的化学和饮食诱导的HCC模型外,随着转基因、转座子、类器官和计算机技术的出现,还产生了一系列新型临床前工具,以克服这一严峻局面。这些模型已迅速成为强大的临床前工具,用于揭示肝癌的分子发病机制并建立针对这种致命疾病的新治疗方法。本综述旨在总结和讨论常用的HCC临床前模型,评估其优缺点。